Reaction

Cd4 Lymphocytes Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,131 reports · 54 co-occurring drugs

As of the last recalculation, Cd4 Lymphocytes Decreased appears in 2,131 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is RITONAVIR 100 MG (PRR 133.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ritonavir 100 Mg	186	133.1	134.8
Darunavir	150	104.1	105.2
Ritonavir	233	87.3	88.0
Alemtuzumab	150	81.4	82.0
Bendamustine Hydrochloride	81	68.6	69.1
Abacavir Sulfate	66	68.3	68.7
Zidovudine	89	67.8	68.2
Lamivudine Oral	162	67.6	68.0
Lamivudine	178	61.3	61.7
Tenofovir Disoproxil Fumarate Tablets	47	54.3	54.6
Efavirenz	55	49.4	49.7
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	88	49.4	49.7
Nevirapine	41	45.2	45.4
Raltegravir	73	44.7	44.9
Lopinavir And Ritonavir	59	43.7	43.9
Cabotegravir	33	40.5	40.7
Atazanavir	58	40.5	40.7
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	34	33.5	33.6
Dolutegravir Sodium	26	28.5	28.6
Tenofovir Disoproxil Fumarate	80	24.5	24.6
Fingolimod Hcl	162	19.7	19.8
Emtricitabine And Tenofovir Disoproxil Fumarate	86	19.1	19.2
Pyrazinamide	14	14.6	14.7
Ganciclovir	15	14.4	14.4
Ganciclovir Sodium	15	13.9	14.0
Daspone	12	12.1	12.1
Dapsone Gel, 5%	12	12.1	12.1
Polatuzumab Vedotin	12	12.1	12.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	11	12.0	12.0
Obinutuzumab	19	11.4	11.4
Emtricitabine And Tenofovir Alafenamide	13	11.3	11.3
Dapsone	12	11.0	11.0
Isoniazid	18	10.9	10.9
Bendamustine Hcl	17	10.8	10.8
Rifampicin	11	10.7	10.7
Anti-Thymocyte Globulin (Rabbit)	8	9.7	9.7
Temozolomide	19	8.9	8.9
Valganciclovir	13	6.8	6.8
Valganciclovir Hydrochloride	13	6.8	6.8
Mycophenilic Acid	13	6.2	6.2
Cladribine	6	6.1	6.1
Axicabtagene Ciloleucel	6	6.0	6.0
Ozanimod Hydrochloride	5	5.9	5.9
Dalfampridine	40	5.5	5.5
Fludarabine Phosphate	21	5.3	5.3
Dimethyl Fumarate	59	4.8	4.8
Ocrelizumab	29	4.6	4.6
Siponimod	4	4.4	4.4
Ofatumumab	13	3.8	3.8
Belimumab	11	3.4	3.4
Vismodegib	3	3.3	3.3
Diroximel Fumarate	4	3.3	3.3
Ribavirin	21	3.2	3.2
Natalizumab	48	2.6	2.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.